Literature DB >> 25070823

Prognostic usefulness of IL-6 and VEGF for the occurrence of changes in coronary arteries of patients with stable angina and implanted stents.

E Kazmierczak1, S Grajek, J Kowal, E Chmara, M Grygier, M Pyda, P Bogdanski, A Cieslewicz, A Jablecka.   

Abstract

AIM: The aim of this study was to determine the prognostic significance of interleukin 6 (IL-6) and vascular endothelial growth factor (VEGF) in patients with chronic coronary artery disease treated who underwent percutaneous coronary intervention with stent implantation, for assessing the risk of restenosis and the occurrence of de novo lesions. PATIENTS AND METHODS: 498 patients with stable angina were examined during 18 months. 50 patients with significant (> 70%) stenosis of one coronary artery, eligible for the implantation of one stent, were enrolled to the study. Il-6 and VEGF level was measured using ELISA immunoassays during the initial coronary angiography with simultaneous angioplasty and stent implantation and 4 weeks after stent implantation. Coronary angiography was carried out 8-12 months after stent implantation.
RESULTS: Statistically significant increase in IL-6 (from 4.02 ± 4.40 to 10.90 ± 8.23) and VEGF (from 310.13 ± 50.90 to 392.32 ± 106.84) level was observed 4 weeks after stent implantation in the group with restenosis.
CONCLUSIONS: Increased levels of IL-6 and VEGF in the peripheral blood of patients with chronic stable angina pectoris, measured 4 weeks after coronary angioplasty with stent implantation, may indicate an increased risk of angiographic restenosis and de novo coronary artery lesions.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25070823

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  5 in total

1.  Age-related limitations of interleukin-6 in predicting early mortality in acute ST-elevation myocardial infarction.

Authors:  Dominika Kanikowska; Małgorzata Pyda; Katarzyna Korybalska; Stefan Grajek; Maciej Lesiak; Andrzej Bręborowicz; Janusz Witowski
Journal:  Immun Ageing       Date:  2014-12-04       Impact factor: 6.400

2.  Inverse Relationship between Serum VEGF Levels and Late In-Stent Restenosis of Drug-Eluting Stents.

Authors:  Jiasheng Yin; Li Shen; Meng Ji; Yizhe Wu; Sishi Cai; Jiahui Chen; Zhifeng Yao; Junbo Ge
Journal:  Biomed Res Int       Date:  2017-03-08       Impact factor: 3.411

3.  Persistent Inflammatory Activity in Blood Cells and Artery Tissue from Patients with Previous Bare Metal Stent.

Authors:  Pedro Silvio Farsky; Mario H Hirata; Renato Tambellini Arnoni; Antonio Flavio Sanches Almeida; Mario Issa; Paula Helena Ortiz Lima; Maria de Lourdes Higuchi; Hui T Lin-Wang
Journal:  Arq Bras Cardiol       Date:  2018-07-16       Impact factor: 2.000

4.  Serum VEGF Predicts Worse Clinical Outcome of Patients with Coronary Heart Disease After Percutaneous Coronary Intervention Therapy.

Authors:  Xia Han; Lili Liu; Jiamin Niu; Jun Yang; Zengtang Zhang; Zhiqiang Zhang
Journal:  Med Sci Monit       Date:  2015-10-26

5.  The Relationships between Polymorphisms in Genes Encoding the Growth Factors TGF-β1, PDGFB, EGF, bFGF and VEGF-A and the Restenosis Process in Patients with Stable Coronary Artery Disease Treated with Bare Metal Stent.

Authors:  Tadeusz Osadnik; Joanna Katarzyna Strzelczyk; Rafał Reguła; Kamil Bujak; Martyna Fronczek; Małgorzata Gonera; Marcin Gawlita; Jarosław Wasilewski; Andrzej Lekston; Anna Kurek; Marek Gierlotka; Przemysław Trzeciak; Michał Hawranek; Zofia Ostrowska; Andrzej Wiczkowski; Lech Poloński; Mariusz Gąsior
Journal:  PLoS One       Date:  2016-03-01       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.